CSF2 and metastatic malignant neoplasm in the lymph nodes: In this regard, FDA-approved intralesional treatment of patients with unresectable melanoma and cutaneous or lymph node metastasis with Talimogen laherparepvec (T-VEC), an oncolytic herpes-simples type 1 virus encoding for granulocyte-macrophage colony-stimulating factor (GM-CSF), has demonstrated to enhance immune response to tumor antigens released after virus replication (152).